Not available
Quote | Merck & Company Inc. (NYSE:MRK)
Last: | $127.51 |
---|---|
Change Percent: | 0.19% |
Open: | $128.01 |
Close: | $127.51 |
High: | $128.48 |
Low: | $127.18 |
Volume: | 6,208,061 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Merck & Company Inc. (NYSE:MRK)
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-04 03:39:35 ET Summary Schwab U.S. Dividend Equity ETF is a popular choice for income-oriented investors, diversification and a defensive approach. SCHD offers exposure to dividend-paying firms with healthy balance sheets, offering investors resilience in turbulent times. ...
Message Board Posts | Merck & Company Inc. (NYSE:MRK)
Subject | By | Source | When |
---|---|---|---|
$MRK reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 1:08:25 PM |
$MRK acquires RXDX for $10.8B | DewDiligence | investorshub | 04/17/2023 4:37:16 PM |
A Delaware judge ruled today that $MRK remains | DewDiligence | investorshub | 04/03/2023 10:07:28 PM |
Keytruda shows statsig-superior PFS as addend to chemo | DewDiligence | investorshub | 03/27/2023 9:52:42 PM |
whytestocks: $MRK News Article - KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved O | whytestocks | investorshangout | 03/10/2023 3:25:48 PM |
News, Short Squeeze, Breakout and More Instantly...
ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrang...
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouragin...
These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA ® (pembrolizum...